Clinical trial
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
NCT00298623 · XenoPort, Inc., Industry · Completed
Key facts
| NCT number | NCT00298623 |
|---|---|
| Title | XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. |
| Lead sponsor | XenoPort, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug, Other |
| Interventions | XP13512 (GSK1838262), placebo |
| Enrollment | 222 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Mar 2, 2006 |
| Last update posted | May 14, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: